Treats asthma as prophylactic therapy. Sold as Cutivate, Flonase, Flovent, Flovent Diskus 50, Flovent Diskus 100 and 6 more. Every FDA application for this active ingredient: 11 branded and 26 generic.
As of Nov 15, 2026, FDA lists 37 applications for Fluticasone Propionate (sold as Cutivate, Flonase, Flovent and others), first approved Dec 14, 1990, with 11 new uses approved and 0 published complete response letters.
| Fluticasone Propionate | Part D | $177M | -7% | 5,260,819 |
| Fluticasone Propionate HFA | Part D | $70.4M | -25% | 86,862 |
| Xhance | Part D | $25.2M | +26% | 9,547 |
| Flovent HFA | Part D | $121K | -99% | 335 |
| Flovent Diskus | Part D | $14K | -99% | 52 |
| Armonair Digihaler | Part D | $0K | -100% | 0 |
| Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic RhinitisChronic Allergic Rhinitis · Dianosic | Phase 1 | Not yet recruiting | Nov 5, 2026 |
| Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaAsthma · Chiesi Farmaceutici S.p.A. | Phase 3 | Not yet recruiting | Oct 5, 2026 |
| A Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic RhinitisRhinitis Allergic, Rhinitis Seasonal · HALEON | Phase 4 | Not yet recruiting | Sep 14, 2026 |
| Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led ModelOral Lichen Planus, Recurrent Aphthous Stomatitis · University of Fujairah | Not applicable | Not yet recruiting | Jul 22, 2026 |
| Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 MonthsAcute Wheezing Disorders in Infants Aged 0 to 24 Months · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | Not yet recruiting | Jun 30, 2026 |
| Novel Method for Removal of Orally Deposited Inhaled Fluticasone PropionateAsthma · University of Wisconsin, Madison | Phase 4 | Not yet recruiting | Jun 24, 2026 |
| Finnish Children´s Protracted CoughChronic Cough · Tampere University Hospital | Phase 3 | Recruiting | May 13, 2026 |
| Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic RhinitisAllergic Rhinitis (AR) · University of Medicine and Pharmacy at Ho Chi Minh City | Not applicable | Active, not recruiting | Apr 17, 2026 |
| Dec 14, 1990 | CutivateNDA 19957 · New molecular entity | Fougera | 13 | Discontinued |
| Dec 18, 1990 | CutivateNDA 19958 · New dosage form | Fougera | 14 | Discontinued |
| Oct 19, 1994 | FlonaseNDA 20121 · New dosage form | Haleon US Holdings | 28 | Discontinued |
| Mar 27, 1996 | FloventNDA 20548 · New dosage form | Glaxosmithkline | 13 | Discontinued |
| Nov 7, 1997 | FloventNDA 20549 · New dosage form | Glaxosmithkline | 12 | Discontinued |
| Sep 29, 2000 | Flovent Diskus 50, Flovent Diskus 100NDA 20833 · New dosage form | Glaxo Grp Ltd | 17 | Marketed |
| May 14, 2004 | Fluticasone PropionateANDA 76300 | Chartwell Rx | 2 | Discontinued |
| May 14, 2004 | Fluticasone PropionateANDA 76451 | Fougera Pharms | 0 | Marketed |
| May 14, 2004 | Fluticasone PropionateANDA 76633 | Encube | 2 | Marketed |
| May 14, 2004 | Fluticasone PropionateANDA 76668 | Padagis Israel | 2 | Marketed |
| May 14, 2004 | Fluticasone PropionateANDA 76793 | Padagis Israel | 1 | Marketed |
| May 14, 2004 | Flovent HfaNDA 21433 · New dosage form | Glaxo Grp Ltd | 19 | Marketed |
| Sep 10, 2004 | Fluticasone PropionateANDA 76865 | Nesher Pharms | 0 | Discontinued |
| Mar 31, 2005 | CutivateNDA 21152 · New dosage form | Fougera | 7 | Discontinued |
| Jun 14, 2005 | Fluticasone PropionateANDA 77145 | Taro Pharm Inds | 1 | Discontinued |
| Feb 22, 2006 | Fluticasone PropionateANDA 76504 | Hikma | 3 | Marketed |
| Mar 3, 2006 | Fluticasone PropionateANDA 77168 | Cosette Pharms Nc | 1 | Marketed |
| Jun 30, 2006 | Fluticasone PropionateANDA 77055 | Cosette Pharms Nc | 0 | Marketed |
| Sep 12, 2007 | Fluticasone PropionateANDA 77538 | Apotex | 3 | Marketed |
| Jan 16, 2008 | Fluticasone PropionateANDA 77570 | Hikma | 3 | Discontinued |
| May 2, 2011 | Fluticasone PropionateANDA 90759 | Glenmark Pharms Ltd | 3 | Discontinued |
| Jan 9, 2012 | Fluticasone PropionateANDA 78492 | Chartwell Rx | 2 | Marketed |
| Jul 30, 2013 | Fluticasone PropionateANDA 91553 | Padagis Israel | 2 | Marketed |
| Jul 23, 2014 | Flonase Allergy ReliefNDA 205434 · TYPE 8 | Haleon US Holdings | 8 | Marketed |
| Feb 29, 2016 | Fluticasone PropionateANDA 208150 | Apotex | 1 | Marketed |
| May 26, 2016 | Fluticasone PropionateANDA 207957 | Hikma | 3 | Marketed |
| Jan 27, 2017 | Armonair Respiclick, Armonair DigihalerNDA 208798 · New formulation or manufacturer | Teva Pharm | 6 | Discontinued |
| Sep 18, 2017 | XhanceNDA 209022 · New formulation or manufacturer | Paratek Pharms | 8 | Marketed |
| Apr 17, 2019 | Fluticasone PropionateANDA 208024 | Hikma | 0 | Discontinued |
| Sep 1, 2023 | Fluticasone PropionateANDA 215343 | Bright | 0 | Discontinued |
| May 10, 2024 | Fluticasone PropionateANDA 217088 | Aurobindo Pharma Ltd | 3 | Marketed |
| Jun 5, 2025 | Fluticasone PropionateANDA 218321 | Rubicon Research | 0 | Marketed |
| Aug 15, 2025 | Fluticasone PropionateANDA 219060 | Rubicon Research | 0 | Marketed |
| Mar 3, 2026 | Fluticasone PropionateANDA 219602 | Glenmark Speclt | 0 | Marketed |
| Mar 16, 2026 | Fluticasone PropionateANDA 218742 | Glenmark Speclt | 0 | Marketed |
| Aug 18, 2026 | Fluticasone PropionateANDA 219232 | Glenmark Speclt | 0 | Marketed |
| Nov 3, 2026 | Fluticasone PropionateANDA 209917 | Teva Pharms USA Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline
Hikma
Apotex